anti-CD3/anti-PSMA bispecific T-cell engager (Bioatla)

N/A

Report date: 2026/03/19 16:53:19

Base Information

Drug Nameanti-CD3/anti-PSMA bispecific T-cell engager (Bioatla)

Drug Alias NamePSMA DualCAB TCECAB-PSMA x CAB-CD3 bispecific antibody (Bioatla)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionProstate-Specific Membrane Antigen modulatorsT lymphocytes stimulantsT cell surface glycoprotein CD3 modulators +[4]

TargetsProstate-Specific Membrane AntigenT cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesBioAtla Inc

China Registration ClassN/A

Develop Information

Active CompaniesBioAtla Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A